Entero Healthcare Solutions Ltd: Valuation Shift Signals Renewed Price Attractiveness

Valuation Metrics: A Closer Look

As of 2 July 2026, Entero Healthcare Solutions Ltd trades at ₹1,190.65, marginally up 0.15% from the previous close of ₹1,188.85. The stock has demonstrated resilience, maintaining a 52-week range between ₹944.00 and ₹1,390.00. The company’s price-to-earnings (P/E) ratio currently stands at 42.33, a figure that, while elevated relative to traditional benchmarks, is considered attractive within its peer group and sector context. This represents a slight moderation from previous levels, contributing to the recent upgrade in valuation grade.

The price-to-book value (P/BV) ratio is 3.06, indicating that the market values the company at just over three times its net asset value. This multiple is consistent with expectations for a small-cap retailing firm with growth prospects, especially when compared to peers exhibiting far higher valuations. For instance, Tata Technologies and Netweb Technologies, both in related sectors, sport P/E ratios of 49.18 and 124.83 respectively, underscoring Entero’s relative valuation appeal.

Enterprise value to EBITDA (EV/EBITDA) is another critical metric, with Entero at 20.85. This multiple is notably lower than several peers such as Data Pattern (66.75) and Zen Technologies (62.74), suggesting that Entero’s earnings before interest, taxes, depreciation, and amortisation are being valued more conservatively, which may appeal to value-conscious investors.

Financial Performance and Returns

Entero’s return on capital employed (ROCE) is 10.74%, while return on equity (ROE) is 7.22%. These figures indicate moderate efficiency in generating profits from capital and shareholder equity, respectively. Although not exceptional, these returns are stable and provide a foundation for sustainable growth, especially when coupled with the company’s improving valuation metrics.

Examining stock returns relative to the benchmark Sensex reveals Entero’s outperformance across multiple time frames. Year-to-date, the stock has gained 16.07%, significantly outperforming the Sensex’s negative 9.74% return. Over the past month, Entero rose 4.27% compared to the Sensex’s 3.58%, and over one week, it advanced 2.34% while the Sensex declined marginally by 0.09%. This consistent relative strength highlights investor confidence and market favour towards Entero’s prospects.

Comparative Valuation: Peer Benchmarking

Within the retailing and technology-related sectors, Entero Healthcare Solutions Ltd’s valuation stands out as attractive when juxtaposed with its peers. Companies such as Tata Elxsi and Indegene are rated as fair in valuation, with P/E ratios of 31.95 and 29.75 respectively, while others like Pine Labs and Cartrade Tech are categorised as very expensive, with P/E multiples exceeding 150 and 59 respectively.

Entero’s PEG ratio of 1.49 further supports its valuation attractiveness. This ratio, which adjusts the P/E for earnings growth, suggests that the stock is reasonably priced relative to its growth prospects. In contrast, Data Pattern’s PEG ratio of 3.96 and Indegene’s 14.87 indicate more stretched valuations, potentially limiting upside for investors seeking value.

Market Capitalisation and Grade Revision

Entero Healthcare Solutions Ltd is classified as a small-cap company, which typically entails higher volatility but also greater growth potential. The recent downgrade in Mojo Grade from Buy to Hold on 27 May 2026 reflects a more cautious stance by analysts, likely influenced by the elevated P/E ratio and moderate returns on equity. However, the valuation grade’s improvement from very attractive to attractive signals that the stock remains a viable option for investors prioritising a balance between growth and valuation discipline.

It is important to note that the company’s dividend yield is currently not available, which may deter income-focused investors. Nonetheless, the focus on capital appreciation and consistent operational delivery may compensate for this absence.

Investment Outlook and Considerations

Entero Healthcare Solutions Ltd’s valuation shift to attractive, combined with its solid relative performance against the Sensex, suggests that the stock is well-positioned for investors seeking exposure to the retailing sector with a growth tilt. The company’s moderate ROCE and ROE indicate operational stability, while its valuation multiples remain reasonable compared to more expensive peers.

However, investors should weigh the recent downgrade in Mojo Grade from Buy to Hold, which signals a tempered outlook amid valuation concerns. The absence of dividend yield also means that total returns will rely heavily on capital gains. Furthermore, the stock’s small-cap status implies higher risk and potential volatility, necessitating a balanced approach within diversified portfolios.

Overall, Entero Healthcare Solutions Ltd offers an attractive valuation entry point relative to its sector and peer group, supported by consistent price appreciation and operational metrics. Investors with a medium to long-term horizon may find value in the stock, particularly if the company continues to deliver steady earnings growth and maintains its market positioning.

Summary of Key Metrics:

• Current Price: ₹1,190.65
• P/E Ratio: 42.33 (Attractive)
• P/BV Ratio: 3.06
• EV/EBITDA: 20.85
• PEG Ratio: 1.49
• ROCE: 10.74%
• ROE: 7.22%
• Mojo Score: 64.0 (Hold)
• Market Cap Grade: Small-cap
• YTD Return: 16.07% vs Sensex -9.74%

Investors should continue to monitor valuation trends and operational performance to assess the stock’s evolving attractiveness within the dynamic retailing landscape.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today